PACIRA BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
PACIRA BIOSCIENCES, INC. (PCRX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$39.00 thousand for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-06-30 was $0.00.
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-03-31 was -$39.00K.
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$236.00K, a 486.89% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $61.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | -$39.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | -$39.00K 10-Q · filed 2025-11-06 | -$298.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$39.00K 10-Q · filed 2025-08-05 | -$298.00K derived: sum of 3 quarters · filed 2026-02-26 | -$136.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | -$39.00K 10-Q · filed 2025-05-08 | -$298.00K derived: sum of 2 quarters · filed 2026-02-26 | -$136.00K derived: sum of 3 quarters · filed 2026-02-26 | |
| 2024-12-31 | -$259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$97.00K derived: sum of 2 quarters · filed 2026-02-26 | -$236.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $23.00K 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | -$139.00K 10-Q · filed 2024-07-30 | |||
| 2023-12-31 | $61.00K 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |